secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001140361-24-008273
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics appoints Peter Cicala to Board of Directors
---------------------------------------------------------------

- Appointed Feb 12, 2024, effective immediately; independent director under Nasdaq rules.
- Serves on Audit, Compensation, and Nominating & Corporate Governance Committees.
- Receives standard non-employee director compensation per 2023 proxy statement.
- No material interest transactions or arrangements with other persons.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036124008273/0001140361-24-008273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036124008273/ef20021627_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-008273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer